Optimising the delivery of tubulin targeting agents through antibody conjugation.

about

Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials Tumour vasculature targeting agents in hybrid/conjugate drugs.Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.

P2860

Q36366709-CFBEB4B5-99F7-4ABD-9D3C-F5D4A6BE394B Q38094627-D1B7166D-AADE-42A6-A894-5557FA8A1A5E Q39117341-FDBD9B53-D35E-4FC7-B07E-9D641E3F028B

P2860

Optimising the delivery of tubulin targeting agents through antibody conjugation.

Item

http://www.wikidata.org/entity/Q38024991

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Optimising the delivery of tubulin targeting agents through antibody conjugation.

@en

type

Item

label

Optimising the delivery of tubulin targeting agents through antibody conjugation.

@en

prefLabel

Optimising the delivery of tubulin targeting agents through antibody conjugation.

@en

P1476

Optimising the delivery of tubulin targeting agents through antibody conjugation.

@en

P2093

Gary D Stack

http://www.w3.org/2001/XMLSchema#string

John J Walsh

http://www.w3.org/2001/XMLSchema#string

P2860

Microtubule-binding agents: a dynamic field of cancer therapeutics.

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

Microtubules as a target for anticancer drugs

A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus

Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules

Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy.

Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.

Antibody-DM1 conjugates as cancer therapeutics.

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Antibody conjugate therapeutics: challenges and potential.

P304

2972-2984

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11095-012-0810-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22777294

http://www.w3.org/2001/XMLSchema#string

Optimising the delivery of tubulin targeting agents through antibody conjugation.

about

P2860

P2860

Optimising the delivery of tubulin targeting agents through antibody conjugation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698